Mélanie Desbois1,2,3 Sylvie Rusakiewicz1,2,4 Clara Locher1,2,3,4 Laurence Zitvogel1,2,3,4† Nathalie Chaput1,2,3,4*†- 1Institut de Cancérologie Gustave Roussy, Villejuif, France
- 2Centre d’Investigation Clinique Biothérapie 507, Institut de cancérologie Gustave Roussy, Villejuif, France
- 3Faculté de Médecine, Université Paris-Sud, Le Kremlin-Bicêtre, France
- 4Institut National de la Santé et de la Recherche Médicale, U1015, Institut de cancérologie Gustave Roussy, Villejuif, France
Natural killer (NK) cells belong to the innate immune system and were initially described functionallywise by their spontaneous cytotoxic potential against transformed or virus-infected cells. A delicate balance between activating and inhibiting receptors regulates NK cell tolerance. A better understanding of tissue resident NK cells, of NK cell maturation stages and migration patterns has evolved allowing a thoughtful evaluation of their modus operandi. While evidence has been brought up for their relevance as gate keepers in some hematopoietic malignancies, the role of NK cells against progression and dissemination of solid tumors remains questionable. Hence, many studies pointed out the functional defects of the rare NK cell infiltrates found in tumor beds and the lack of efficacy of adoptively transferred NK cells in patients. However, several preclinical evidences suggest their anti-metastatic role in a variety of mouse tumor models. In the present review, we discuss NK cell functions according to their maturation stage and environmental milieu, the receptor/ligand interactions dictating tumor cell recognition and recapitulate translational studies aimed at deciphering their prognostic or predictive role against human solid malignancies.
NK Cell Functions are Dictated by their Stage of Maturation and the Microenvironment
Natural killer (NK) cells can have distinct functions depending on their maturation stage and the microenvironment, rendering complex the physio-pathological role attributed to NK cells. The majority of mature NK cells circulate in the peripheral blood, but are also resident in several lymphoid and non-lymphoid organs, such as the spleen, tonsils, lymph nodes (LNs), liver, lungs, intestine, and uterus (Shi et al., 2011).
Mouse NK Cells
In mice, the phenotype of NK cells is defined among lymphocytes as CD3-NK1.1+NKp46+. Mature NK (mNK) cells are identified by the expression of the integrin CD11b (Kim et al., 2002) and can be further subdivided into various subsets according to the differentiation marker CD27 (Hayakawa and Smyth, 2006). In adoptive transfer experiments, CD11b− immature NK (iNK) cells pass through the CD27+ stage prior to reaching the terminal CD27−CD11b+ stage (Chiossone et al., 2009). CD27+ NK cells harbored greater cytotoxic function, proliferation capacity, and interferon-γ (IFN-γ) secretion after stimulation with interleukin (IL)-12 and/or IL-18 than the CD27− expressing counterparts. CXCR3 is exclusively expressed by the CD11b+CD27+ NK cell subset, endowing cells with an active chemotaxis toward CXCR3 ligands (CXCL10, IP-10, CXCL11) and a preferred migration to lymphoid tissues (Hayakawa and Smyth, 2006). Hence, CD11b+CD27− NK cells are considered terminally differentiated, long-lived cells, preferentially located in non-lymphoid tissues and exhibiting a functional restriction by self-major histocompatibility complexes (MHC; Figure 1).
FIGURE 1. Maturation stage of NK cells. (A) In mice, the maturation stage of CD3− NK1.1+ NKp46+ NK cells is defined using both CD27 and CD11b molecule expressions. Upper panel shows relative proportions of NK cells at steady state in bone marrow (BM), lymph nodes (LN), spleen, liver, blood, and lungs. Lower panel shows the differentiation of NK cells based on the expression of CD27 and CD11b. IKDCs expressing B220 and CD11c molecules would be part of a premature NK cell fraction (pre-mNK) and of a CD27-positive fraction of mature NK cells also expressing the mannose receptor (CD206). NKreg cells have an immature phenotype in that they are CD27-positive and CD11b-negative. (B) In humans, CD19−CD3−CD56+ NK cells are generally defined by high expression (bright) or intermediate (dim) expression of the CD56 molecule. As in mice, these two populations (CD56bright and CD56dim) are enriched in separate compartments: CD56bright NK cells predominate in lymph nodes while CD56dim NK cells predominate in peripheral blood. Various studies suggested that NK cells expressing CD56dim would be more terminally differentiated compared to NK cells expressing CD56bright.
A recent study described a premature NK cell subset (pre-mNK; Guimont-Desrochers et al., 2012) preceding the CD27+ mNK cell stage. This NK cell stage may correspond to the interferon-producing killer dendritic cells (IKDC) described in 2006 (Chan et al., 2006; Taieb et al., 2006). Indeed, Taieb et al. (2006) and others (Chan et al., 2006) described CD11cint B220+CD49b+NK1.1+MHC-II+ cells sharing both antigen presentation and cytotoxic functions culminating in anti-tumor activity (Taieb et al., 2006). Guimont-Desrochers et al. (2012) showed that mNK cells fail to acquire B220, even after in vivo stimulation, suggesting that CD11cint B220+ NK cells may not merely result from NK cell activation (Vosshenrich et al., 2007). They showed that, by 5 days post-transfer, CD11cint B220+CD49b+ NK cells down-regulated CD11c, B220, and CD27, and acquired CD43, in agreement with functional maturation. By 25 days post-transfer, all B220+ NK cells had completely lost B220 expression and exhibited a CD11cneg/low CD11b+CD27− phenotype compatible with terminally differentiated NK cells. These pre-mNK cells were actively cycling, a characteristic associated with precursor cell populations (Guimont-Desrochers et al., 2012). Thus, CD27+ CD11blow CD49b+ CD11cint B220+ NK cells could be defined as pre-mNK cells, an immediate precursor to CD27+ CD11b+ NK cells. Moreover, our data pointed out that half of IKDCs were CD11b+. Such CD11b+CD27+IKDCs expressed the mannose receptor (CD206) accounting for ovalbumin (OVA) protein uptake and OVA-specific CD8+ T cell priming in vivo. Thus, we reported that the mature fraction of IKDCs could exert antigen-presentation capacity (Terme et al., 2009).
Interestingly, among the iNK cells (defined as CD11b−CD27+), we recently identified a distinct subset endowed with regulatory functions (that we named “NKreg”). NK cells defined as CD27+ CD11blow c-Kit+ NKp46+ NK cells expressed molecules associated with immunosuppressive functions (such as CTLA4, Lag-3, and PDL-1). These Kit+ NK cells accumulated in primary and secondary lymphoid organs of tumor bearers in an IL-18-dependent fashion. Blockade of tumor-derived IL-18 markedly prevented NKreg accumulation and melanoma dissemination. Kit+ NK cells operated their immunosuppressive effect by directly killing immature dendritic cells (DC) and indirectly reducing the pool of peripheral mNK cells. Anti-PD1 or anti-PDL-1 neutralizing antibodies counteracted all these immunosuppressive effects. Hence, the adoptive transfer of NKreg cells promoted tumor outgrowth and metastases spreading (Terme et al., 2012). Our study is in accordance with others describing iNK cells with regulatory functions. In a mouse model of leukemia, CD49b+ CD90bright c-Kitdim NK cells expanded; compromised DC maturation and could blunt allogeneic T cell proliferation (Ebata et al., 2006). Hence, these data indicate that distinct subsets of “imNK” could exert intrinsic inhibitory functions. In addition, mNK may secrete suppressive cytokines and exert regulatory functions in pathology such as infections, autoimmunity, and transplantation. Perona-Wright et al. (2009) showed that NK cells could secrete IL-10 during the acute phase of systemic infections. NK cell-derived IL-10 hampered the expression of MHC and co-stimulatory molecules and suppressed the production of pro-inflammatory cytokines by DC (Perona-Wright et al., 2009). In autoimmune disease, NK3-like cells secreting transforming growth factor beta (TGF-β) could protect mice against type I diabetes (Zhou et al., 2007). NK cells promoted allograft tolerance (Beilke et al., 2005) and reduced graft versus host disease (GVHD) by limiting allogeneic T cell proliferation (Noval Rivas et al., 2010), presumably through eradication of myeloid DC.
Finally, NK cells from extra-medullary tissues harboring tissue-specific phenotypes suggest that the maturation can be completed in organ different from bone marrow including thymus, liver, uterus, and gut. Thymic NK cells have several peculiarities compared with “conventional” NK cells: (i) they express high levels of IL-7Rα chain (CD127) and the transcription factor GATA-3, (ii) they produce cytokines but display low natural cytotoxicity, (iii) they accumulate in LNs (Vosshenrich et al., 2006). Uterine NK cells promote vascular remodeling and influence the recruitment and activation of other leukocytes to regulate the physiology of pregnancy (Santoni et al., 2007). In the liver, bone marrow-derived NK cells migrate into the liver where they differentiate into liver-specific NK cells (Vanderkerken et al., 1993). Hepatic NK cells display potent cytotoxic capacity expressing high levels of TRAIL, granzyme B, and perforin molecules (Ochi et al., 2004; Takeda et al., 2005). A recent study has shown that CD11c+ NK cells could play a major role during adenoviral hepatitis (Burt et al., 2008), these CD11c+ NK cells gained a modest antigen-presenting cell capacity thus functionally resembling to NKDCs (Pillarisetty et al., 2005; Plitas et al., 2007) or IKDCs (Taieb et al., 2006). Finally, CXCL16 (the ligand for CXCR6) is constitutively secreted by the liver sinusoidal endothelium leading to the accumulation of CXCR6+ NK cells that represent a consistent fraction of liver NK cells. CXCR6+ NK cells are drastically reduced in CXCR6 knockout mice. CXCR6-expressing NK cell has been suggested to develop an adaptive-like immunity, memory NK cell development depend on CXCR6 expression by NK cells a chemokine receptor required for the maintenance of these memory NK cells (Paust et al., 2010). In the mouse intestine, two subsets of NKp46+ cells are present in the gut (Satoh-Takayama et al., 2008). Conventional NK cells secrete IFN-γ and lack expression of RORγt, whereas RORγt+ NKp46+ cells secrete IL-22 (also called “NK22”) following stimulation with IL-23 and do not require IL-15 for their differentiation (Luci et al., 2009). IL-15-dependent NKp46+ NK cells represent the major source of CCL3 during -induced ileitis leading to the recruitment of CCR1+ inflammatory monocytes (Schulthess et al., 2012). However, IL-18 (and not IL-15) favored CCL3 secretion by these intestinal and pathogenic NK cells (Schulthess et al., 2012). The authors discussed the possibility that such pathogenic NK cells could cause the recruitment of inflammatory monocytes in Crohn’s disease (Schulthess et al., 2012). However, it is of note that the precise lineage of gut mucosa associated-NKp46+ cells remains debated and it is still unclear if they are developmentally related to the NK cells and/or to the lymphoid tissue inducer cells or if they represent a distinct innate immunity cell types (Colonna, 2009; Spits and Di Santo, 2011).
Human NK Cells
In humans, the blood NK cell pool (CD19−CD3−CD56+ among lymphocytes) is commonly divided into two distinct subsets, based on the surface intensity of CD56 expression and the low-affinity Fc receptor CD16. A major population of CD56dim NK cells (roughly 90%) expresses high levels of CD16, whereas a minor subset of CD56bright NK cells fails to express CD16 (Lanier et al., 1986). Moreover, CD56dim NK cells exert high levels of killer cell immunoglobulin-like receptors (KIR) and low levels of CD94/NKG2 receptors in contrast to CD56bright NK cells (Figure 1). These two populations were shown to differ functionally in that CD16low CD56bright are considered more potent cytokine producers while CD16high CD56dim NK cells display higher cytotoxic functions. Only CD56dim cells mediate CD16-dependent antibody-dependent cell-mediated cytotoxicity (ADCC; Cooper et al., 2001). However, although CD56bright NK cells can produce high amounts of cytokine after 24 h stimulation with IL-12 or IL-18, CD56dim cells also produce high quantities of cytokine after engagement of the activating receptors or after short-term cytokine stimulation (Fauriat et al., 2010; De Maria et al., 2011). This notion suggests that extrinsic factors (dictated by microenvironmental cues or soluble factors) may shape NK cell functions regardless of their “so called maturation stage.” Hence, CD56dim and CD56bright NK cells differ in their in vivo localization. CD56bright NK cells express chemokine receptors (such as CCR7, CXCR3, and CD62L) favoring a preferential migration into lymphoid organs (LN) and a privileged interaction with LN-residing antigen-presenting cells (Campbell et al., 2001; Cooper et al., 2001). In contrast, CD56dim NK cells are enriched in tonsils, lungs, mucosal sites, and the uterus (Ferlazzo et al., 2004). As a corollary to the murine data, CD27 has been shown to be expressed by the CD56bright fraction of human NK cells and by LN resident NK cells in humans (Silva et al., 2008; Vossen et al., 2008). Analogous to the relationship between CD27+ and CD27− mNK cells in mice, CD27+CD56bright NK cells are considered as the immature subset of human circulating NK cells (Silva et al., 2008; Vossen et al., 2008).
Apart from blood and lymphoid tissues, organ-specific distribution and function of NK cells has been described. NK cells are present in normal liver and aid to control tolerance and homeostasis (Doherty and O’Farrelly, 2000), a dialog between Kupffer cells and NK cells allowing the tuning of hepatic NK cells during infection or liver injury (Tu et al., 2008). Half of hepatic NK cells are CD56bright CD16low, express CCR7 and CXCR3, the inhibitory molecule NKG2A and high levels of TRAIL. Liver TRAIL-expressing NK cells contribute to hepatocellular damage and clearance of hepatitis C virus (Dunn et al., 2007; Stegmann et al., 2010). In the uterus (Whitelaw and Croy, 1996), in situ development of NK cells from precursors is induced by IL-15 and stem cell factor (SCF). NK cells can also be recruited by extravillous trophoblast (EVT) via CXCL12 secretion. Activated NK cells secrete IFN-γ that participate in the remodeling of spiral arteries. Decidual stromal cells secrete TGF-β that results in the down-regulation of CD16 expression, thus decreasing the ADCC of NK cells. Expression of HLA-C2 haplotype on EVT predisposes for preeclampsia (Hiby et al., 2004; Parham, 2004). In the mucosa surrounding the lymphoid follicles of tonsils and Peyer’s patches of the ileum/appendix, innate cells referred to as NK22 express the activating receptor NKp44 as well as the chemokine receptor CCR6 and may promote mucosal homeostasis (Cella et al., 2009). The expression of CC-chemokine receptor 8 (CCR8) and cutaneous leukocyte antigen (CLA) is restricted to human skin-resident NK cells. Skin NK cells are mostly CD56+/CD16low and display strong cytotoxic activity against melanoma cells (Ebert et al., 2006).
Collectively, these data support the theory that the maturation stage of NK cells and environmental factors may cooperate to shape their functional activities, as already described for other innate cells such as DC. Although, in steady-state conditions, mNK cells can be found in some lymphoid and non-lymphoid organs, following an insult such as a infection, inflammation, or cancer, specialized NK cell subsets can be rapidly recruited to injured organs to perform their specific function (elimination of danger) and/or re-establish tissue integrity.
NK Cells are Able to Recognize Tumor Cells
Tumor cells expose several ligands that can be recognized by NK cells rendering tumor susceptible to NK cell attack. Interestingly, accumulating evidences showed that NK cell-mediated elimination of tumor cells will lead to the subsequent development of tumor-specific T cell responses against the parental tumor cells (Diefenbach et al., 2001; Kelly et al., 2002).
Molecules Implicated in the Recognition of Tumors by NK Cells
For more than 20 years, several lines of evidence demonstrated the important role of NK cells in the control of solid malignancies. The pioneering demonstration was conducted in the beige mouse in 1980 (Talmadge et al., 1980). Beige mice mimics human Chediak–Higashi syndrome presenting with defective natural cytotoxicity against tumor cells. Using a NK cell sensitive (but not resistant) tumor cell line, Talmadge et al. reported increased growth rate, faster induction time and increased metastatic dissemination of tumors established in beige compared to control mice. Later, depletion experiments using anti-asialoGM-1 or anti-NK1.1 antibodies concluded to the crucial role of mouse NK cells in keeping in check tumor growth and metastatic spread (Gorelik et al., 1982; Aboud et al., 1993; Smyth et al., 2001). Conversely, adoptive NK cell transfer could restore resistance to metastatic spreading, establishing a causal link between NK cells and tumor control in wild-type mice (Gorelik et al., 1982; Aboud et al., 1993; Smyth et al., 2000, 2001; Street et al., 2001). Moreover, a prominent role for Ly49 receptors (Ljunggren and Karre, 1985; Karre et al., 1986; Glas et al., 1992, 2000; Koh et al., 2001), NK group 2 member D (NKG2D) activating receptors (Diefenbach et al., 2001), DNAX accessory molecule-1 (DNAM-1; Lakshmikanth et al., 2009), and components of the NK cell secretory and cytotoxic machinery (Street et al., 2001; Takeda et al., 2011), TRAIL (Taieb et al., 2006) was reported in the control of tumor growth and metastases in mice.
In addition, translational research in patients argues on the role of NK cells in immunosurveillance against cancer (Imai et al., 2000; Guerra et al., 2008; Kreisel et al., 2012). The KIR (Moretta et al., 1996) and CD94/NKG2A heterodimers (Braud et al., 1998) participate in the regulation of NK cell activation by tumor cells. Indeed, tumor cells can down-regulate MHC class I expression the missing self-engagement of NK cell activation favoring tumor elimination (Vivier et al., 2012). Next to this mechanism, stress-induced molecules also activate NK cells. NKG2D plays an important role in the recognition of stress-induced molecules such as the polymorphic MHC class I chain-related molecules (MIC)A and MICB human (Groh et al., 1996; Bauer et al., 1999) and the cytomegalovirus UL-16 protein (ULBP; Cosman et al., 2001). Such proteins are frequently expressed in primary carcinomas (Pende et al., 2002; Vetter et al., 2002; Friese et al., 2003; Watson et al., 2006). The identification of two NKG2D haplotypes associated with differential NK cytotoxic potential and risk of cancer illustrates the importance of NKG2D in the anti-tumor immunosurveillance (Hayashi et al., 2006). Natural cytotoxicity receptors (NCR) are also implicated in the destruction of tumor cells. All three NCRs are implicated in the clearance of a variety of tumors, including carcinomas, melanomas, and neuroblastomas. Among self-ligands expressed by tumor cells and able to activate NK cells, heparan sulfate moieties of heparin sulfate proteoglycans have been described as self-modified ligands for NCRs (Jayson et al., 1998; Blackhall et al., 2001), these ligands being rarely expressed on normal cells (Bloushtain et al., 2004; Hershkovitz et al., 2007, 2008; Cagnano et al., 2008; Hecht et al., 2009; Jarahian et al., 2011). NKp30, NKp44, and NKp46 recognize highly sulfated heparan sulfate/heparin-type structures (Hecht et al., 2009). B7 homolog 6 (B7-H6), absent from normal cells but expressed on the K562 cell line and other acute myeloid leukemia and solid tumors, was identified as a ligand for NKp30. Moreover, nuclear factors (up-regulated or disturbed in their distribution) represent alternate ligands for NCRs. Hence, HLA-B-associated transcript 3 (BAT3) was identified as a ligand for NKp30 activating NK cells. BAT3 can be either re-localized at the cell surface or expressed on tumor-derived exosomes shed in the extracellular milieu (Pogge von Strandmann et al., 2007; Simhadri et al., 2008). Finally, proliferating cell nuclear antigen (PCNA) which is highly expressed in proliferating cells and associated with malignancy (Stoimenov and Helleday, 2009) was shown to be recruited in the immunological synapse formed between NK and tumor cells, leading to inhibitory triggering of NKp44 receptors (Rosental et al., 2011).
Nk Cells Constrain Metastatic Dissemination
Several cell autonomous features resulting in NK cell recruitment and/or activation have been described. Hence, the interferon regulatory factor irf7 is a key molecule limiting bone metastases in a NK and CD8+ T cell-dependent manner (Bidwell et al., 2012). Enforcing irf7 expression by tumor cells could restore type I IFN signaling, leading to inhibition of metastatic dissemination in the 4T1.2 breast cancer bone metastasis model (Lelekakis et al., 1999; Eckhardt et al., 2005). Differences in gene expression profiles of tumor cells isolated from matched pairs of primary tumors and bone metastases revealed that a high number of IFN-related genes were down-regulated in bone metastases including irf7 (Bidwell et al., 2012). 4T1.2 clones overexpressing IRF7 were able to produce significant levels of IFN-α compared to the 4T1.2 control cell line. 4T1.2-irf7+ presented with reduced dissemination to the bones in an IFNAR1-dependent manner. Depletion of CD4+, CD8+, and NK cells demonstrated that CD8+ and NK cells (but not CD4+ T cells) were needed for the irf7-dependent anti-metastatic effect (Bidwell et al., 2012). Treatment with 105 IU of recombinant IFN-α could reduce bone metastases in mice bearing the 4T1.2 tumors, causing the up-regulation of irf7, irf9, and STAT1 in the wild-type 4T1.2 cell line. Finally, authors showed that defective irf7 signaling pathway in human breast cancers was significantly associated with bone metastases as the first site of dissemination (Bidwell et al., 2012). Moreover, irf1 expression by the tumor was mandatory for NK cell-dependent suppression of metastases (Ksienzyk et al., 2011). Here, irf1 was implicated in the suppression of lung metastases, but not tumor spreading to the bone (Bidwell et al., 2012). Both type I and II IFNs were dispensable for the NK cell-mediated resistance to lung metastases. Irf1 expression by tumor cells was associated with an increased CXCL11/CXCR3-dependent NK cell infiltration of lung nodules. Moreover, irf1 could induce tumor cell surface expression of MHC class I molecules, death receptor DR5 and adhesion molecule CD155 (ligand for DNAM-1). Hence, NK cell-mediated elimination of lung metastases was mainly dependent on DNAM-1 receptors and only partially on TRAIL molecules (Ksienzyk et al., 2011). Altogether, these lines of evidence indicate the cell intrinsic role of interferon-related pathways in the control of metastatic dissemination by NK cells. Moreover, various subsets of NK cells appear to control bone (Bidwell et al., 2012) or lung (Ksienzyk et al., 2011) dissemination. Indeed, while CD27+ NK cells prevailed against bone marrow metastases (Bidwell et al., 2012), terminally differentiated NK cells seem to control lung metastases (Sceneay et al., 2012). Indeed, over 80% of lung NK cells are mature CD11b+ cells.
In contrast, other reports point to a role for myeloid cells in suppressing the function of mNK in metastatic niches. Sceneay et al. (2012) reported that hypoxia at the primary tumor site led to enhanced secretion of soluble factors that favor metastatic dissemination. Particularly, under hypoxic conditions, soluble factors secreted by the primary tumor induce the recruitment of bone marrow-derived cells in the lungs. Hypoxia caused the accumulation of granulocytic CD11b+/Ly6Cmed/Ly6G+ myeloid cells through a monocyte chemoattractant protein 1 (MCP1)-dependent mechanism as well as that of iNK cells (CD11b−/CD27−) endowed with poor anti-tumor effector functions. Authors assume that CD11b+/Ly6Cmed/Ly6G+ myeloid cells could inhibit NK cell differentiation, as myeloid cell accumulation has been inversely correlated with suppression of NK cell function in murine tumor models (Liu et al., 2007; Mauti et al., 2011). In methylcholanthrene-induced carcinogenesis as well as transplantable metastases models, NLRP3 inflammasome was shown to support metastases formation. Expansion of CD11b+ Gr1int myeloid cells within the lung tumor microenvironment of NLRP3 knockout mice was concomitant with increased lung infiltrating activated NK cells and an improved anti-metastatic response. These myeloid cells secreted CCL5 and CXCL9 chemokines favoring the trafficking of NK cells into metastatic lungs (Chow et al., 2012).
Considering that NK cells can regulate metastatic dissemination, it remains unclear whether NK cells are able to modify the metastatic potential of primary tumor cells and premetastatic niche and/or could represent an efficient innate barrier that could prevent tumor cell implantation. To our knowledge, scarce data exist demonstrating that NK cells could modify tumor cells in the primary tumor in a way that would decrease metastatic potential. Some data suggested that NK cells could have cytotoxic activity against cancer stem cells, which represent a more chemo- and radio-resistant subpopulation within cancer (Tseng et al., 2010; Jewett and Tseng, 2011; Jewett et al., 2012). Considering accumulating evidence incriminating tumor stemness as a risk factor for metastatic relapse (van Zijl et al., 2009; Raimondi et al., 2010; Yu et al., 2012), high NK cell infiltration in the primary tumor could be a good biomarker associated with low risk of metastatic relapse. Recently, the epithelial-mesenchymal transition (EMT) process was linked to the gain of stem cell competence (Mani et al., 2008; Polyak and Weinberg, 2009). Thus, EMT favors the generation of tumor cells with self-renewing properties and high proliferative capacity, enhancing their chances to seed at a distant site and to grow metastases. Factors that can influence EMT and/or stemness such as hypoxia and TGF-β (Das et al., 2008; Heddleston et al., 2009) are also known to inhibit NK cell functions. Thus, it is conceivable that agents reinvigorating NK cells in the tumor bed could decrease its metastatic potential and thus reduce time to relapse.
In humans, NK cell infiltration (determined with different NK cell markers, i.e., CD57, CD56, NKp46, CD3, and CD56) is often studied on a tumor burden after curative resection. Interestingly, NK cell infiltrates are often associated with a lower risk of relapse and/or longer survival (Table 1). However, in most cases, NK cell numbers are limited compared with other effectors as reported using tissue microarrays of melanomas (Erdag et al., 2012; Sconocchia et al., 2012), hepatocellular carcinomas (Sconocchia et al., 2012), breast cancers (Sconocchia et al., 2012), renal cell carcinomas (Sconocchia et al., 2009), and colon rectal cancers (Sconocchia et al., 2010). Very low NK cell infiltration could be monitored in these different solid tumors, except for colorectal carcinomas where 38% of tumor samples appeared to be infiltrated by NK cells (Sconocchia et al., 2010, 2012). Furthermore, the activation status of NK cells infiltrating the tumor and/or tumor niches might play a crucial role in tumor clearance and/or prevention of tumor spreading. Many reports in cancer patients have demonstrated that NK cells have altered cytotoxic functions usually correlated with down-regulation of NCR while tumor cells usually express ligands for these NCR (Menard et al., 2009; Mamessier et al., 2011a,b; Platonova et al., 2011).
TABLE 1. Tumor infiltrating NK cells in human cancers.
Over the past decade, we investigated the role of NK cells in the control of gastrointestinal sarcomas (GIST). Unexpected long-term responses to imatinib mesylate (IM) have been reported in GIST lacking the hallmark molecular criteria of responses to IM (Borg et al., 2004; Menard et al., 2009), suggesting that IM might mediate part of its therapeutic effect by an off-target effect. Indeed, several mouse tumor cell lines that did not respond to IM in vitro did so in vivo in immunocompetent mice. This therapeutic off-target effect of IM was mediated by NK cells and/or specialized DC subsets (Borg et al., 2004). We found that, by inhibiting c-Kit in DC, IM could promote a DC/NK cross-talk that ultimately stimulates NK cells to produce IFN-γ both in mice and in humans (Borg et al., 2004). Importantly, the IM-induced IFN-γ production by NK cells represented an independent predictor of long-term survival in advanced GIST treated with IM (Menard et al., 2009). Since IM failed to trigger NK cell IFN-γ production in about half of GIST patients, we launched a comprehensive analysis of the GIST-associated NK cell phenotype. At diagnosis, circulating NK cells from GIST patients (compared with healthy volunteers) exhibited a selective down-regulation of one particular type of stimulatory NK cell receptor, NKp30, but not that of another type, NKG2D, and this NKp30 down-regulation was only partially restored by IM (Menard et al., 2009). We demonstrated that the alternative splicing of exon 4, which affects the intracellular domain of NKp30, generates three membrane-bound proteins with distinct functions. Indeed, the NKp30a isoform could stimulate NK cell degranulation and Th1-type cytokine secretion, while the NKp30b isoform only signals for Th1 cytokine secretion and the NKp30c isoform transduced a delayed signal leading to IL-10 secretion. In a cohort of 80 patients with metastatic or recurrent GIST, the predominant expression of NKp30c was associated with decreased NKp30-dependent TNFα and CD107a release, compared to patients with high expression of NKp30a and/or NKp30b. The predominant expression of the NKp30c isoform was an independent prognostic factor of reduced overall survival (Delahaye et al., 2011). Freshly dissociated tumor samples revealed that GIST are highly infiltrated with NK cells (roughly 25% of CD45+ leukocytes were CD3−CD56+ NK cells), and the density of NK cell infiltration was inversely correlated with metastases at diagnosis (Delahaye et al., 2011). Altogether, these data again support a more preventive than curative role for NK cells by counteracting metastatic spread. Since NK cells could play a crucial role in controlling tumor dissemination in GIST patients, we developed strategies for boosting NK cells along with IM treatment. Association of IM and IL-2 has been shown to have potent anti-tumor responses in mice through activation and trafficking of IKDC to lung metastases (Taieb et al., 2006). From 2009 to 2012, we launched a phase I clinical trial in patients with refractory solid tumors to determine the maximum tolerated dose of IL-2 combined with 400 mg daily IM. Data from this clinical trial will be reported soon. If the association appears to be non-toxic, a phase II study in GIST patients combining these two compounds will be considered. Other NK cell stimulatory compounds to be used in synergy with IM against GIST could be envisaged (Figure 2).
FIGURE 2. Therapeutic strategies that could increase the functions of NK cells in patients with GIST. NK cells of patients with high expression of NKp30a and/or NKp30b isoforms could be reinvigorated using treatments that are know to favor either direct activation (IL-2, IFN-α, IL-15, sushi-IL-15) or indirect activation (FLT3, cyclophosphamide) of NK cells along with imatinib mesylate treatment. Since Balachandran et al. (2011) have shown that CD8+ T cells could favor tumor regression it is conceivable to use drugs that will favor CD8 T cell activation (anti-PD1 or anti-CTLA4). In patients harboring the wrong NKp30 profile (high expression of NKp30c isoform) blocking IL-10 or IL-10 receptor (IL-10R) or using agent that could modify the NKp30 profile toward the NKp30ab profile (methyltransferase inhibitors?) might restore the NKp30-dependant NK cells function, thus favoring the control of tumor growth and/or dissemination.
Thereby, it seems that NK cells could be a potent effector cells preventing tumor formation (immunosurveillance) and/or limiting metastatic spread. Previous study by Imai et al. (2000) had anticipated this type of conclusion in humans. This 11-year follow-up study showed a reduced cancer risk among people with strong or medium natural cytotoxic functions in peripheral blood, suggesting a role for natural immunological host defense mechanisms against cancer. However, and as described above, NK cells have difficulty entering the tumor therefore, strategies that could increase the penetration and/or proliferation and/or local differentiation of NK cells in the tumor remain attractive. Recently, the B16F10 transplantable mouse melanoma model transfected with chemerin, a chemoattractant for NK cells, macrophages, and DC subsets (Wittamer et al., 2003; Zabel et al., 2005; Parolini et al., 2007), led to a significant recruitment of NK cells in the tumor responsible for tumor regression (Pachynski et al., 2012). The authors showed that intra-tumor injection of the recombinant chemerin was sufficient to obtain tumor regression. Finally, in two independent clinical cohorts of melanoma patients, retention of high RARRES2 (a gene encoding the chemoattractant chemerin) expression correlated with better clinical outcomes (Pachynski et al., 2012).
Concluding Remarks
We are entering a new era of NK cell investigations in human malignancies that will open up new avenues for NK cell identification and profiling. How NK cell trafficking to tumors and/or differentiate from precursors in tumors remain an active conundrum. How NK cells prevent metastases is obscure. How NK cells regulate adaptive immunity is still debated since NK can shut down or instead trigger DC or CD4+ T cells. How to strengthen the functions of NK cells and/or neutralize the immunosuppressive factors should be harnessed (e.g., IL-2, IL-15, sushi IL-15, IFN-α, and peptide inhibitors of TGF-β1; Figure 2).
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Abbreviations
AM, alveolar macrophages; CCL2, CC-chemokine ligand 2; CCL5, CC-chemokine ligand 5; CCR2, CC-chemokine receptor 2; CCR5, CC-chemokine receptor 5; CCR8, CC-chemokine receptor 8; CD, cluster of differentiation; CLA, cutaneous leukocyte antigen; CSF1R, colony stimulating factor 1 receptor; CX3CL1, CX3C-chemokine ligand 1; CX3CR1, CX3C-chemokine receptor 1; CXCL10, CXC-chemokine ligand 10; CXCL11, chemokine (C-X-C motif) ligand 11; CXCL12, CXC-chemokine ligand 12; CXCR3, CXC-chemokine receptor 3; CXCR6, CXC-chemokine receptor 6; DC, dendritic cell; DSC, decidual stromal cells; EVT, extravillous trophoblast; GIST, gastrointestinal stromal tumor; HCV, hepatitis C virus; HLA, human leukocyte antigen; IBD, intestinal bowel diseases; IFN-α, interferon-α; IFN-γ, interferon-γ; IFNAR1, interferon (alpha, beta, omega) receptor 1; IL, interleukin; IM, imatinib mesylate; IP-10, interferon gamma-induced protein 10; KIR, killer cell Ig-like receptor; KLRG1, killer cell lectin-like receptor subfamily G member 1; MCSF, macrophage colony-stimulating factor; NCR, natural cytotoxicity receptors; NK cells, natural killer cells; PD-1, programmed cell death protein-1; PD-L1, programmed cell death 1 ligand 1; RANK, receptor activator of nuclear factor κB; RANKL, receptor activator of nuclear factor κ-B ligand; SA, spiral arteries; TRAIL, TNF-related apoptosis-inducing ligand; Treg, regulatory T cell.
References
Aboud, M., Kingsmore, S., and Segal, S. (1993). Role of natural killer cells in controlling local tumor formation and metastatic manifestation of different 3LL Lewis lung carcinoma cell clones. Nat. Immunol. 12, 17–24.
Al-Shibli, K., Al-Saad, S., Donnem, T., Persson, M., Bremnes, R. M., and Busund, L. T. (2009). The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology 55, 301–312.
Balachandran, V. P., Cavnar, M. J., Zeng, S., Bamboat, Z. M., Ocuin, L. M., Obaid, H., et al. (2011). Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat. Med. 17, 1094–1100.
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., et al. (1999). Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285, 727–729.
Beilke, J. N., Kuhl, N. R., Van Kaer, L., and Gill, R. G. (2005). NK cells promote islet allograft tolerance via a perforin-dependent mechanism. Nat. Med. 11, 1059–1065.
Bidwell, B. N., Slaney, C. Y., Withana, N. P., Forster, S., Cao, Y., Loi, S., et al. (2012). Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med. doi: 10.1038/nm.2830 [Epub ahead of print].
Blackhall, F. H., Merry, C. L., Davies, E. J., and Jayson, G. C. (2001). Heparan sulfate proteoglycans and cancer. Br. J. Cancer 85, 1094–1098.
Bloushtain, N., Qimron, U., Bar-Ilan, A., Hershkovitz, O., Gazit, R., Fima, E., et al. (2004). Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J. Immunol. 173, 2392–2401.
Borg, C., Jalil, A., Laderach, D., Maruyama, K., Wakasugi, H., Charrier, S., et al. (2004). NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood 104, 3267–3275.
Braud, V. M., Allan, D. S., O’Callaghan, C. A., Soderstrom, K., D’Andrea, A., Ogg, G. S., et al. (1998). HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391, 795–799.
Burt, B. M., Plitas, G., Stableford, J. A., Nguyen, H. M., Bamboat, Z. M., Pillarisetty, V. G., et al. (2008). CD11c identifies a subset of murine liver natural killer cells that responds to adenoviral hepatitis. J. Leukoc. Biol. 84, 1039–1046.
Cagnano, E., Hershkovitz, O., Zilka, A., Bar-Ilan, A., Golder, A., Sion-Vardy, N., et al. (2008). Expression of ligands to NKp46 in benign and malignant melanocytes. J. Invest. Dermatol. 128, 972–979.
Cameron, S., Haller, F., Dudas, J., Moriconi, F., Gunawan, B., Armbrust, T., et al. (2008). Immune cells in primary gastrointestinal stromal tumors. Eur. J. Gastroenterol. Hepatol. 20, 327–334.
Campbell, J. J., Qin, S., Unutmaz, D., Soler, D., Murphy, K. E., Hodge, M. R., et al. (2001). Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire. J. Immunol. 166, 6477–6482.
Carrega, P., Morandi, B., Costa, R., Frumento, G., Forte, G., Altavilla, G., et al. (2008). Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer 112, 863–875.
Cella, M., Fuchs, A., Vermi, W., Facchetti, F., Otero, K., Lennerz, J. K., et al. (2009). A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 457, 722–725.
Chan, C. W., Crafton, E., Fan, H. N., Flook, J., Yoshimura, K., Skarica, M., et al. (2006). Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat. Med. 12, 207–213.
Chiossone, L., Chaix, J., Fuseri, N., Roth, C., Vivier, E., and Walzer, T. (2009). Maturation of mouse NK cells is a 4-stage developmental program. Blood 113, 5488–5496.
Chow, M. T., Sceneay, J., Paget, C., Wong, C. S., Duret, H., Tschopp, J., et al. (2012). NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases. Cancer Res. 72, 5721–5732.
Colonna, M. (2009). Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity. Immunity 31, 15–23.
Cooper, M. A., Fehniger, T. A., and Caligiuri, M. A. (2001). The biology of human natural killer-cell subsets. Trends Immunol. 22, 633–640.
Cosman, D., Mullberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., et al. (2001). ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14, 123–133.
Das, B., Tsuchida, R., Malkin, D., Koren, G., Baruchel, S., and Yeger, H. (2008). Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells 26, 1818–1830.
De Maria, A., Bozzano, F., Cantoni, C., and Moretta, L. (2011). Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc. Natl. Acad. Sci. U.S.A. 108, 728–732.
Delahaye, N. F., Rusakiewicz, S., Martins, I., Menard, C., Roux, S., Lyonnet, L., et al. (2011). Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat. Med. 17, 700–707.
Diefenbach, A., Jensen, E. R., Jamieson, A. M., and Raulet, D. H. (2001). Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413, 165–171.
Doherty, D. G., and O’Farrelly, C. (2000). Innate and adaptive lymphoid cells in the human liver. Immunol. Rev. 174, 5–20.
Dunn, C., Brunetto, M., Reynolds, G., Christophides, T., Kennedy, P. T., Lampertico, P., et al. (2007). Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J. Exp. Med. 204, 667–680.
Ebata, K., Shimizu, Y., Nakayama, Y., Minemura, M., Murakami, J., Kato, T., et al. (2006). Immature NK cells suppress dendritic cell functions during the development of leukemia in a mouse model. J. Immunol. 176, 4113–4124.
Ebert, L. M., Meuter, S., and Moser, B. (2006). Homing and function of human skin gammadelta T cells and NK cells: relevance for tumor surveillance. J. Immunol. 176, 4331–4336.
Eckhardt, B. L., Parker, B. S., Van Laar, R. K., Restall, C. M., Natoli, A. L., Tavaria, M. D., et al. (2005). Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol. Cancer Res. 3, 1–13.
Erdag, G., Schaefer, J. T., Smolkin, M. E., Deacon, D. H., Shea, S. M., Dengel, L. T., et al. (2012). Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 72, 1070–1080.
Fauriat, C., Long, E. O., Ljunggren, H. G., and Bryceson, Y. T. (2010). Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 115, 2167–2176.
Ferlazzo, G., Thomas, D., Lin, S. L., Goodman, K., Morandi, B., Muller, W. A., et al. (2004). The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J. Immunol. 172, 1455–1462.
Friese, M. A., Platten, M., Lutz, S. Z., Naumann, U., Aulwurm, S., Bischof, F., et al. (2003). MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res. 63, 8996–9006.
Gannon, P. O., Poisson, A. O., Delvoye, N., Lapointe, R., Mes-Masson, A. M., and Saad, F. (2009). Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J. Immunol. Methods 348, 9–17.
Glas, R., Franksson, L., Une, C., Eloranta, M. L., Ohlen, C., Orn, A., et al. (2000). Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype. An adaptive component of NK cell-mediated responses. J. Exp. Med. 191, 129–138.
Glas, R., Sturmhofel, K., Hammerling, G. J., Karre, K., and Ljunggren, H. G. (1992). Restoration of a tumorigenic phenotype by beta 2-microglobulin transfection to EL-4 mutant cells. J. Exp. Med. 175, 843–846.
Gorelik, E., Wiltrout, R. H., Okumura, K., Habu, S., and Herberman, R. B. (1982). Role of NK cells in the control of metastatic spread and growth of tumor cells in mice. Int. J. Cancer 30, 107–112.
Groh, V., Bahram, S., Bauer, S., Herman, A., Beauchamp, M., and Spies, T. (1996). Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad. Sci. U.S.A. 93, 12445–12450.
Guerra, N., Tan, Y. X., Joncker, N. T., Choy, A., Gallardo, F., Xiong, N., et al. (2008). NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28, 571–580.
Guimont-Desrochers, F., Boucher, G., Dong, Z., Dupuis, M., Veillette, A., and Lesage, S. (2012). Redefining interferon-producing killer dendritic cells as a novel intermediate in NK-cell differentiation. Blood 119, 4349–4357.
Gulubova, M., Manolova, I., Kyurkchiev, D., Julianov, A., and Altunkova, I. (2009). Decrease in intrahepatic CD56+ lymphocytes in gastric and colorectal cancer patients with liver metastases. APMIS 117, 870–879.
Halama, N., Braun, M., Kahlert, C., Spille, A., Quack, C., Rahbari, N., et al. (2011). Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin. Cancer Res. 17, 678–689.
Hayakawa, Y., and Smyth, M. J. (2006). CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J. Immunol. 176, 1517–1524.
Hayashi, T., Imai, K., Morishita, Y., Hayashi, I., Kusunoki, Y., and Nakachi, K. (2006). Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance. Cancer Res. 66, 563–570.
Hecht, M. L., Rosental, B., Horlacher, T., Hershkovitz, O., De Paz, J. L., Noti, C., et al. (2009). Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan sulfate/heparin sequences. J. Proteome Res. 8, 712–720.
Heddleston, J. M., Li, Z., Mclendon, R. E., Hjelmeland, A. B., and Rich, J. N. (2009). The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 8, 3274–3284.
Hershkovitz, O., Jarahian, M., Zilka, A., Bar-Ilan, A., Landau, G., Jivov, S., et al. (2008). Altered glycosylation of recombinant NKp30 hampers binding to heparan sulfate: a lesson for the use of recombinant immunoreceptors as an immunological tool. Glycobiology 18, 28–41.
Hershkovitz, O., Jivov, S., Bloushtain, N., Zilka, A., Landau, G., Bar-Ilan, A., et al. (2007). Characterization of the recognition of tumor cells by the natural cytotoxicity receptor, NKp44. Biochemistry 46, 7426–7436.
Hiby, S. E., Walker, J. J., O’Shaughnessy K, M., Redman, C. W., Carrington, M., Trowsdale, J., et al. (2004). Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J. Exp. Med. 200, 957–965.
Imai, K., Matsuyama, S., Miyake, S., Suga, K., and Nakachi, K. (2000). Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356, 1795–1799.
Izawa, S., Kono, K., Mimura, K., Kawaguchi, Y., Watanabe, M., Maruyama, T., et al. (2011). H(2)O(2) production within tumor microenvironment inversely correlated with infiltration of CD56(dim) NK cells in gastric and esophageal cancer: possible mechanisms of NK cell dysfunction. Cancer Immunol. Immunother. 60, 1801–1810.
Jarahian, M., Fiedler, M., Cohnen, A., Djandji, D., Hammerling, G. J., Gati, C., et al. (2011). Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutinin. PLoS Pathog. 7:e1002195. doi: 10.1371/journal.ppat.1002195
Jayson, G. C., Lyon, M., Paraskeva, C., Turnbull, J. E., Deakin, J. A., and Gallagher, J. T. (1998). Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J. Biol. Chem. 273, 51–57.
Jewett, A., and Tseng, H. C. (2011). Tumor induced inactivation of natural killer cell cytotoxic function; implication in growth, expansion and differentiation of cancer stem cells. J. Cancer 2, 443–457.
Jewett, A., Tseng, H. C., Arasteh, A., Saadat, S., Christensen, R. E., and Cacalano, N. A. (2012). Natural killer cells preferentially target cancer stem cells; role of monocytes in protection against NK cell mediated lysis of cancer stem cells. Curr. Drug Deliv. 9, 5–16.
Karre, K., Ljunggren, H. G., Piontek, G., and Kiessling, R. (1986). Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319, 675–678.
Kelly, J. M., Darcy, P. K., Markby, J. L., Godfrey, D. I., Takeda, K., Yagita, H., et al. (2002). Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat. Immunol. 3, 83–90.
Kim, S., Iizuka, K., Kang, H. S., Dokun, A., French, A. R., Greco, S., et al. (2002). In vivo developmental stages in murine natural killer cell maturation. Nat. Immunol. 3, 523–528.
Koh, C. Y., Blazar, B. R., George, T., Welniak, L. A., Capitini, C. M., Raziuddin, A., et al. (2001). Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 97, 3132–3137.
Kreisel, D., Gelman, A. E., Higashikubo, R., Lin, X., Vikis, H. G., White, J. M., et al. (2012). Strain-specific variation in murine natural killer gene complex contributes to differences in immunosurveillance for urethane-induced lung cancer. Cancer Res. 72, 4311–4317.
Ksienzyk, A., Neumann, B., Nandakumar, R., Finsterbusch, K., Grashoff, M., Zawatzky, R., et al. (2011). IRF-1 expression is essential for natural killer cells to suppress metastasis. Cancer Res. 71, 6410–6418.
Lakshmikanth, T., Burke, S., Ali, T. H., Kimpfler, S., Ursini, F., Ruggeri, L., et al. (2009). NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J. Clin. Invest. 119, 1251–1263.
Lanier, L. L., Le, A. M., Civin, C. I., Loken, M. R., and Phillips, J. H. (1986). The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J. Immunol. 136, 4480–4486.
Lelekakis, M., Moseley, J. M., Martin, T. J., Hards, D., Williams, E., Ho, P., et al. (1999). A novel orthotopic model of breast cancer metastasis to bone. Clin. Exp. Metastasis 17, 163–170.
Liu, C., Yu, S., Kappes, J., Wang, J., Grizzle, W. E., Zinn, K. R., et al. (2007). Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 109, 4336–4342.
Ljunggren, H. G., and Karre, K. (1985). Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J. Exp. Med. 162, 1745–1759.
Luci, C., Reynders, A., Ivanov, I. I., Cognet, C., Chiche, L., Chasson, L., et al. (2009). Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin. Nat. Immunol. 10, 75–82.
Mamessier, E., Sylvain, A., Bertucci, F., Castellano, R., Finetti, P., Houvenaeghel, G., et al. (2011a). Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. Cancer Res. 71, 6621–6632.
Mamessier, E., Sylvain, A., Thibult, M. L., Houvenaeghel, G., Jacquemier, J., Castellano, R., et al. (2011b). Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J. Clin. Invest. 121, 3609–3622.
Mani, S. A., Guo, W., Liao, M. J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704–715.
Marechal, R., De Schutter, J., Nagy, N., Demetter, P., Lemmers, A., Deviere, J., et al. (2010). Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients. BMC Cancer 10:340. doi: 10.1186/1471-2407-10-340
Mauti, L. A., Le Bitoux, M. A., Baumer, K., Stehle, J. C., Golshayan, D., Provero, P., et al. (2011). Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation. J. Clin. Invest. 121, 2794–2807.
Menard, C., Blay, J. Y., Borg, C., Michiels, S., Ghiringhelli, F., Robert, C., et al. (2009). Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res. 69, 3563–3569.
Menon, A. G., Janssen-Van Rhijn, C. M., Morreau, H., Putter, H., Tollenaar, R. A., Van De Velde, C. J., et al. (2004). Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab. Invest. 84, 493–501.
Moretta, A., Bottino, C., Vitale, M., Pende, D., Biassoni, R., Mingari, M. C., et al. (1996). Receptors for HLA class-I molecules in human natural killer cells. Annu. Rev. Immunol. 14, 619–648.
Noval Rivas, M., Hazzan, M., Weatherly, K., Gaudray, F., Salmon, I., and Braun, M. Y. (2010). NK cell regulation of CD4 T cell-mediated graft-versus-host disease. J. Immunol. 184, 6790–6798.
Ochi, M., Ohdan, H., Mitsuta, H., Onoe, T., Tokita, D., Hara, H., et al. (2004). Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice. Hepatology 39, 1321–1331.
Pachynski, R. K., Zabel, B. A., Kohrt, H. E., Tejeda, N. M., Monnier, J., Swanson, C. D., et al. (2012). The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses. J. Exp. Med. 209, 1427–1435.
Park, M. H., Lee, J. S., and Yoon, J. H. (2012). High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma. J. Surg. Oncol. 106, 386–392.
Parolini, S., Santoro, A., Marcenaro, E., Luini, W., Massardi, L., Facchetti, F., et al. (2007). The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood 109, 3625–3632.
Paust, S., Gill, H. S., Wang, B. Z., Flynn, M. P., Moseman, E. A., Senman, B., et al. (2010). Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat. Immunol. 11, 1127–1135.
Pende, D., Rivera, P., Marcenaro, S., Chang, C. C., Biassoni, R., Conte, R., et al. (2002). Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 62, 6178–6186.
Perona-Wright, G., Mohrs, K., Szaba, F. M., Kummer, L. W., Madan, R., Karp, C. L., et al. (2009). Systemic but not local infections elicit immunosuppressive IL-10 production by natural killer cells. Cell Host Microbe 6, 503–512.
Pillarisetty, V. G., Katz, S. C., Bleier, J. I., Shah, A. B., and Dematteo, R. P. (2005). Natural killer dendritic cells have both antigen presenting and lytic function and in response to CpG produce IFN-gamma via autocrine IL-12. J. Immunol. 174, 2612–2618.
Platonova, S., Cherfils-Vicini, J., Damotte, D., Crozet, L., Vieillard, V., Validire, P., et al. (2011). Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res. 71, 5412–5422.
Plitas, G., Chaudhry, U. I., Kingham, T. P., Raab, J. R., and Dematteo, R. P. (2007). NK dendritic cells are innate immune responders to Listeria monocytogenes infection. J. Immunol. 178, 4411–4416.
Pogge von Strandmann, E., Simhadri, V. R., Von Tresckow, B., Sasse, S., Reiners, K. S., Hansen, H. P., et al. (2007). Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 27, 965–974.
Polyak, K., and Weinberg, R. A. (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 9, 265–273.
Raimondi, C., Gianni, W., Cortesi, E., and Gazzaniga, P. (2010). Cancer stem cells and epithelial-mesenchymal transition: revisiting minimal residual disease. Curr. Cancer Drug Targets 10, 496–508.
Rosental, B., Brusilovsky, M., Hadad, U., Oz, D., Appel, M. Y., Afergan, F., et al. (2011). Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. J. Immunol. 187, 5693–5702.
Sandel, M. H., Speetjens, F. M., Menon, A. G., Albertsson, P. A., Basse, P. H., Hokland, M., et al. (2005). Natural killer cells infiltrating colorectal cancer and MHC class I expression. Mol. Immunol. 42, 541–546.
Santoni, A., Zingoni, A., Cerboni, C., and Gismondi, A. (2007). Natural killer (NK) cells from killers to regulators: distinct features between peripheral blood and decidual NK cells. Am. J. Reprod. Immunol. 58, 280–288.
Satoh-Takayama, N., Vosshenrich, C. A., Lesjean-Pottier, S., Sawa, S., Lochner, M., Rattis, F., et al. (2008). Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity 29, 958–970.
Sceneay, J., Chow, M. T., Chen, A., Halse, H. M., Wong, C. S., Andrews, D. M., et al. (2012). Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res. 72, 3906–3911.
Schulthess, J., Meresse, B., Ramiro-Puig, E., Montcuquet, N., Darche, S., Begue, B., et al. (2012). Interleukin-15-dependent NKp46+ innate lymphoid cells control intestinal inflammation by recruiting inflammatory monocytes. Immunity 37, 108–121.
Sconocchia, G., Arriga, R., Tornillo, L., Terracciano, L., Ferrone, S., and Spagnoli, G. C. (2012). Melanoma cells inhibit NK cell functions – letter. Cancer Res. 72, 5428–5429.
Sconocchia, G., Spagnoli, G. C., Del Principe, D., Ferrone, S., Anselmi, M., Wongsena, W., et al. (2009). Defective infiltration of natural killer cells in MICA/B-positive renal cell carcinoma involves beta(2)-integrin-mediated interaction. Neoplasia 11, 662–671.
Sconocchia, G., Zlobec, I., Lugli, A., Calabrese, D., Iezzi, G., Karamitopoulou, E., et al. (2010). Tumor infiltration by FcgammaRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int. J. Cancer 128, 2663–2672.
Shi, F. D., Ljunggren, H. G., La Cava, A., and Van Kaer, L. (2011). Organ-specific features of natural killer cells. Nat. Rev. Immunol. 11, 658–671.
Silva, A., Andrews, D. M., Brooks, A. G., Smyth, M. J., and Hayakawa, Y. (2008). Application of CD27 as a marker for distinguishing human NK cell subsets. Int. Immunol. 20, 625–630.
Simhadri, V. R., Reiners, K. S., Hansen, H. P., Topolar, D., Simhadri, V. L., Nohroudi, K., et al. (2008). Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PLoS ONE 3:e3377. doi: 10.1371/journal.pone.0003377
Smyth, M. J., Crowe, N. Y., and Godfrey, D. I. (2001). NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol. 13, 459–463.
Smyth, M. J., Thia, K. Y., Street, S. E., Macgregor, D., Godfrey, D. I., and Trapani, J. A. (2000). Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 192, 755–760.
Spits, H., and Di Santo, J. P. (2011). The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat. Immunol. 12, 21–27.
Stegmann, K. A., Bjorkstrom, N. K., Veber, H., Ciesek, S., Riese, P., Wiegand, J., et al. (2010). Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 138, 1885–1897.
Stoimenov, I., and Helleday, T. (2009). PCNA on the crossroad of cancer. Biochem. Soc. Trans. 37, 605–613.
Street, S. E., Cretney, E., and Smyth, M. J. (2001). Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 97, 192–197.
Taieb, J., Chaput, N., Menard, C., Apetoh, L., Ullrich, E., Bonmort, M., et al. (2006). A novel dendritic cell subset involved in tumor immunosurveillance. Nat. Med. 12, 214–219.
Takanami, I., Takeuchi, K., and Giga, M. (2001). The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. J. Thorac. Cardiovasc. Surg. 121, 1058–1063.
Takeda, K., Cretney, E., Hayakawa, Y., Ota, T., Akiba, H., Ogasawara, K., et al. (2005). TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver. Blood 105, 2082–2089.
Takeda, K., Nakayama, M., Sakaki, M., Hayakawa, Y., Imawari, M., Ogasawara, K., et al. (2011). IFN-gamma production by lung NK cells is critical for the natural resistance to pulmonary metastasis of B16 melanoma in mice. J. Leukoc. Biol. 90, 777–785.
Talmadge, J. E., Meyers, K. M., Prieur, D. J., and Starkey, J. R. (1980). Role of NK cells in tumour growth and metastasis in beige mice. Nature 284, 622–624.
Terme, M., Mignot, G., Ullrich, E., Bonmort, M., Minard-Colin, V., Jacquet, A., et al. (2009). The dendritic cell-like functions of IFN-producing killer dendritic cells reside in the CD11b+ subset and are licensed by tumor cells. Cancer Res. 69, 6590–6597.
Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Coudert, J. D., Desbois, M., et al. (2012). Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Res. 72, 2757–2767.
Tseng, H. C., Arasteh, A., Paranjpe, A., Teruel, A., Yang, W., Behel, A., et al. (2010). Increased lysis of stem cells but not their differentiated cells by natural killer cells; de-differentiation or reprogramming activates NK cells. PLoS ONE 5:e11590. doi: 10.1371/journal.pone.0011590
Tu, Z., Bozorgzadeh, A., Pierce, R. H., Kurtis, J., Crispe, I. N., and Orloff, M. S. (2008). TLR-dependent cross talk between human Kupffer cells and NK cells. J. Exp. Med. 205, 233–244.
van Zijl, F., Zulehner, G., Petz, M., Schneller, D., Kornauth, C., Hau, M., et al. (2009). Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncol. 5, 1169–1179.
Vanderkerken, K., Bouwens, L., De Neve, W., Van Den Berg, K., Baekeland, M., Delens, N., et al. (1993). Origin and differentiation of hepatic natural killer cells (pit cells). Hepatology 18, 919–925.
Vetter, C. S., Groh, V., Thor Straten, P., Spies, T., Brocker, E. B., and Becker, J. C. (2002). Expression of stress-induced MHC class I related chain molecules on human melanoma. J. Invest. Dermatol. 118, 600–605.
Villegas, F. R., Coca, S., Villarrubia, V. G., Jimenez, R., Chillon, M. J., Jareno, J., et al. (2002). Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 35, 23–28.
Vivier, E., Ugolini, S., Blaise, D., Chabannon, C., and Brossay, L. (2012). Targeting natural killer cells and natural killer T cells in cancer. Nat. Rev. Immunol. 12, 239–252.
Vossen, M. T., Matmati, M., Hertoghs, K. M., Baars, P. A., Gent, M. R., Leclercq, G., et al. (2008). CD27 defines phenotypically and functionally different human NK cell subsets. J. Immunol. 180, 3739–3745.
Vosshenrich, C. A., Garcia-Ojeda, M. E., Samson-Villeger, S. I., Pasqualetto, V., Enault, L., Richard-Le Goff, O., et al. (2006). A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat. Immunol. 7, 1217–1224.
Vosshenrich, C. A., Lesjean-Pottier, S., Hasan, M., Richard-Le Goff, O., Corcuff, E., Mandelboim, O., et al. (2007). CD11cloB220+ interferon-producing killer dendritic cells are activated natural killer cells. J. Exp. Med. 204, 2569–2578.
Watson, N. F., Spendlove, I., Madjd, Z., Mcgilvray, R., Green, A. R., Ellis, I. O., et al. (2006). Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. Int. J. Cancer 118, 1445–1452.
Wittamer, V., Franssen, J. D., Vulcano, M., Mirjolet, J. F., Le Poul, E., Migeotte, I., et al. (2003). Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J. Exp. Med. 198, 977–985.
Yu, Y., Ramena, G., and Elble, R. C. (2012). The role of cancer stem cells in relapse of solid tumors. Front. Biosci. (Elite Ed.) 4, 1528–1541.
Zabel, B. A., Silverio, A. M., and Butcher, E. C. (2005). Chemokine-like receptor 1 expression and chemerin-directed chemotaxis distinguish plasmacytoid from myeloid dendritic cells in human blood. J. Immunol. 174, 244–251.
Keywords: NK cells, maturation stage, environment, tumors, metastases
Citation: Desbois M, Rusakiewicz S, Locher C, Zitvogel L and Chaput N (2012) Natural killer cells in non-hematopoietic malignancies. Front. Immun. 3:395. doi: 10.3389/fimmu.2012.00395
Received: 16 November 2012; Paper pending published: 05 December 2012;
Accepted: 06 December 2012; Published online: 24 December 2012.
Edited by:
Eric Vivier, Centre d’Immunologie de Marseille Luminy, FranceReviewed by:
Björn önfelt, Karolinska Institutet, SwedenTeresa Bellon, Hospital La Paz Health Research Institute, Spain
Copyright: © 2012 Desbois, Rusakiewicz, Locher, Zitvogel and Chaput. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
*Correspondence: Nathalie Chaput, Centre d’Investigation Clinique Biothérapie 507, Institut de cancérologie Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif Cedex, France. e-mail: nathalie.chaput@igr.fr
†Laurence Zitvogel and Nathalie Chaput have contributed equally to this work.